These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 32575541)
1. Discovery of Isoplumbagin as a Novel NQO1 Substrate and Anti-Cancer Quinone. Tsao YC; Chang YJ; Wang CH; Chen L Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575541 [TBL] [Abstract][Full Text] [Related]
2. NADPH: Quinone oxidoreductase 1 (NQO1) mediated anti-cancer effects of plumbagin in endocrine resistant MCF7 breast cancer cells. Pradubyat N; Sakunrangsit N; Mutirangura A; Ketchart W Phytomedicine; 2020 Jan; 66():153133. PubMed ID: 31790893 [TBL] [Abstract][Full Text] [Related]
3. An Axis between the Long Non-Coding RNA Nakashima C; Fujiwara-Tani R; Mori S; Kishi S; Ohmori H; Fujii K; Mori T; Miyagawa Y; Yamamoto K; Kirita T; Luo Y; Kuniyasu H Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142607 [TBL] [Abstract][Full Text] [Related]
4. Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy. Ma X; Huang X; Moore Z; Huang G; Kilgore JA; Wang Y; Hammer S; Williams NS; Boothman DA; Gao J J Control Release; 2015 Feb; 200():201-11. PubMed ID: 25542645 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of 3-(1-benzotriazole)-nor-β-lapachones as NQO1-directed antitumor agents. Wu LQ; Ma X; Liu ZP Bioorg Chem; 2021 Aug; 113():104995. PubMed ID: 34034133 [TBL] [Abstract][Full Text] [Related]
6. NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer. Li LS; Reddy S; Lin ZH; Liu S; Park H; Chun SG; Bornmann WG; Thibodeaux J; Yan J; Chakrabarti G; Xie XJ; Sumer BD; Boothman DA; Yordy JS Mol Cancer Ther; 2016 Jul; 15(7):1757-67. PubMed ID: 27196777 [TBL] [Abstract][Full Text] [Related]
7. Rational designed highly sensitive NQO1-activated near-infrared fluorescent probe combined with NQO1 substrates in vivo: An innovative strategy for NQO1-overexpressing cancer theranostics. Gong Q; Yang F; Hu J; Li T; Wang P; Li X; Zhang X Eur J Med Chem; 2021 Nov; 224():113707. PubMed ID: 34303080 [TBL] [Abstract][Full Text] [Related]
8. A direct interaction between NQO1 and a chemotherapeutic dimeric naphthoquinone. Pidugu LS; Mbimba JC; Ahmad M; Pozharski E; Sausville EA; Emadi A; Toth EA BMC Struct Biol; 2016 Jan; 16():1. PubMed ID: 26822308 [TBL] [Abstract][Full Text] [Related]
9. Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: Design, synthesis, and in vivo antitumor evaluation. Li X; Bian J; Wang N; Qian X; Gu J; Mu T; Fan J; Yang X; Li S; Yang T; Sun H; You Q; Zhang X Bioorg Med Chem; 2016 Mar; 24(5):1006-13. PubMed ID: 26803578 [TBL] [Abstract][Full Text] [Related]
10. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism. Silvers MA; Deja S; Singh N; Egnatchik RA; Sudderth J; Luo X; Beg MS; Burgess SC; DeBerardinis RJ; Boothman DA; Merritt ME J Biol Chem; 2017 Nov; 292(44):18203-18216. PubMed ID: 28916726 [TBL] [Abstract][Full Text] [Related]
11. β-Lapachone Induces NAD(P)H:Quinone Oxidoreductase-1- and Oxidative Stress-Dependent Heat Shock Protein 90 Cleavage and Inhibits Tumor Growth and Angiogenesis. Wu Y; Wang X; Chang S; Lu W; Liu M; Pang X J Pharmacol Exp Ther; 2016 Jun; 357(3):466-75. PubMed ID: 27048660 [TBL] [Abstract][Full Text] [Related]
12. Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels. Reinicke KE; Bey EA; Bentle MS; Pink JJ; Ingalls ST; Hoppel CL; Misico RI; Arzac GM; Burton G; Bornmann WG; Sutton D; Gao J; Boothman DA Clin Cancer Res; 2005 Apr; 11(8):3055-64. PubMed ID: 15837761 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of (±)-dunnione and its ortho-quinone analogues as substrates for NAD(P)H:quinone oxidoreductase 1 (NQO1). Bian J; Xu L; Deng B; Qian X; Fan J; Yang X; Liu F; Xu X; Guo X; Li X; Sun H; You Q; Zhang X Bioorg Med Chem Lett; 2015 Mar; 25(6):1244-8. PubMed ID: 25677663 [TBL] [Abstract][Full Text] [Related]
14. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1. Dehn DL; Winski SL; Ross D Clin Cancer Res; 2004 May; 10(9):3147-55. PubMed ID: 15131056 [TBL] [Abstract][Full Text] [Related]
15. Low doses of methylnaltrexone inhibits head and neck squamous cell carcinoma growth in vitro and in vivo by acting on the mu-opioid receptor. Gorur A; Patiño M; Shi T; Corrales G; Takahashi H; Rangel R; Gleber-Netto FO; Pickering C; Myers JN; Cata JP J Cell Physiol; 2021 Nov; 236(11):7698-7710. PubMed ID: 34038587 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs. Phillips RM; Jaffar M; Maitland DJ; Loadman PM; Shnyder SD; Steans G; Cooper PA; Race A; Patterson AV; Stratford IJ Biochem Pharmacol; 2004 Dec; 68(11):2107-16. PubMed ID: 15498501 [TBL] [Abstract][Full Text] [Related]
17. YM155 Down-Regulates Survivin and Induces P53 Up-Regulated Modulator of Apoptosis (PUMA)-Dependent in Oral Squamous Cell Carcinoma Cells. Yan X; Su H Med Sci Monit; 2017 Apr; 23():1963-1972. PubMed ID: 28435150 [TBL] [Abstract][Full Text] [Related]
18. 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo. Dehn DL; Siegel D; Zafar KS; Reigan P; Swann E; Moody CJ; Ross D Mol Cancer Ther; 2006 Jul; 5(7):1702-9. PubMed ID: 16891456 [TBL] [Abstract][Full Text] [Related]
19. Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer. Wu X; Li X; Li Z; Yu Y; You Q; Zhang X J Med Chem; 2018 Dec; 61(24):11280-11297. PubMed ID: 30508483 [TBL] [Abstract][Full Text] [Related]
20. Nanotechnology-enabled delivery of NQO1 bioactivatable drugs. Ma X; Moore ZR; Huang G; Huang X; Boothman DA; Gao J J Drug Target; 2015; 23(7-8):672-80. PubMed ID: 26453163 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]